Indivior Pharmaceuticals, Inc. (INDV)

Over the last 12 months, Indivior's stock price has increased significantly. Key events impacting INDV's stock include the completion of its redomiciliation from the United Kingdom to the United States in January 2026. The company concluded a legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million. Indivior was included in the S&P SmallCap 600® index in December 2025. In the third quarter of 2025, Indivior reported an increase in patients receiving Sublocade treatment and revised its guidance for worldwide Sublocade sales. In July 2025, Indivior reported solid second-quarter financial results, leading to raised full-year 2025 financial guidance. First-quarter 2025 results were in line with expectations, with Sublocade net revenue consistent with full-year 2025 guidance. In February 2025, Indivior reported a 9% increase in full-year 2024 net revenue, driven by Sublocade growth, but projected a 17% decline in overall net revenue for 2025.

The overall market for opioid use disorder treatments may be growing, product-specific demand can be impacted by competitive landscapes and regulatory factors rather than explicit seasonal patterns. The company has observed continued growth in U.S. buprenorphine medication-assisted treatments. Sublocade has shown solid growth, while Suboxone Film has experienced declining net revenue due to intensified generic competition.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling prescription drugs for substance use disorders and other serious mental illnesses. Its major products include Sublocade, Suboxone, Subutex, Perseris, and Opvee. In January 2026, Indivior completed its redomiciliation, moving its corporate headquarters from the UK to the US.

The vast majority of Indivior's revenue is generated in the United States, followed by the United Kingdom and the rest of the world. The company's portfolio of products is available in 37 countries and engages in the discovery, development, and commercialization of therapeutics in Europe, Canada, and Japan.

Indivior's brand reputation has been influenced by its ongoing efforts to address past legal challenges and its focus on its core mission. Indivior concluded a legacy U.S. Department of Justice matter by paying an outstanding obligation of $295 million. Currently, Indivior emphasizes its commitment to ethical business practices, patient safety, and fighting the stigma associated with addiction.

Indivior Pharmaceuticals, Inc. has 239 institutional owners and shareholders holding a total of 374,578,762 shares. Major institutional shareholders include Oaktree Capital Management Lp, Two Seas Capital LP, BlackRock, Inc., Deerfield Management Company, L.p. (series C), Goldman Sachs Group Inc, Madison Avenue Partners, LP, Morgan Stanley, Vanguard Group Inc, Newtyn Management, LLC, and Divisadero Street Capital Management, LP. Institutional ownership accounts for 86.4% of the company, with individual insiders holding 3.47%.